Volume : 13, Issue : 11, November – 2026
Title:
EVALUATION OF ANTIPARKINSONS AND MONOAMINE OXIDASE-MAO-B INHIBITORY PROPERTIES OF SENNA OCCIDENTALIS IN RATS
Authors :
T SINDHUJA, I VEENA RANI *
Abstract :
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra, leading to motor and non-motor dysfunction. The present study was designed to evaluate the antiparkinsonian and monoamine oxidase-B (MAO-B) inhibitory activity of Senna occidentalis in MPTP-induced Parkinsonian rats. Parkinsonism was induced by administration of MPTP (25 mg/kg, i.p.), and animals were divided into five groups: vehicle control, MPTP control, standard drug (Levodopa 12 mg/kg + Benserazide 3 mg/kg), and Senna occidentalis extract at doses of 200 mg/kg and 400 mg/kg (p.o.).
Behavioral assessments including rotarod, open field, hole board, forced swimming, and tail suspension tests were performed to evaluate motor coordination, locomotor activity, and behavioral despair. Biochemical parameters such as dopamine levels, MAO-B activity, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), glutathione peroxidase (GPx), and nitric oxide (NO) were estimated in brain tissue. MPTP administration produced significant motor impairment, increased oxidative stress, elevated MAO-B activity, and reduced dopamine levels.
Treatment with Senna occidentalis significantly improved behavioral performance and biochemical parameters in a dose-dependent manner. The higher dose (400 mg/kg) showed more pronounced neuroprotective effects, comparable to the standard drug. The protective effect may be attributed to the presence of phytoconstituents such as flavonoids, phenolics, alkaloids, and terpenoids, which exert antioxidant and MAO-B inhibitory actions.
In conclusion, Senna occidentalis exhibits significant antiparkinsonian activity through modulation of oxidative stress, inhibition of MAO-B enzyme, and restoration of dopaminergic function, suggesting its potential as a neuroprotective agent in Parkinson’s disease.
Keywords: Parkinson’s disease, MPTP, Senna occidentalis, MAO-B inhibition, oxidative stress, dopamine, neuroprotection, antioxidant activity.
Cite This Article:
Please cite this article in press I Veena Rani et al., Evaluation Of Antiparkinsons And Monoamine Oxidase-Mao-B Inhibitory Properties Of Senna Occidentalis In Rats.,. Indo Am. J. P. Sci, 2026; 13(11).
REFERENCES:
1. Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318(1):215–24. PMID: 15503155.
2. Höglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci. 2004;7(7):726–35. PMID: 15195095.
3. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909. PMID: 12971891.
4. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3(12):1301–6. PMID: 11100120.
5. Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson’s disease. Neurobiol Dis. 2003;13(1):25–34. PMID: 12901805.
6. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc. 2007;2(1):141–51. PMID: 17406547.
7. Blandini F, Armentero MT. Animal models of Parkinson’s disease. FEBS J. 2012;279(7):1156–66. PMID: 22320367.
8. Bové J, Perier C. Neurotoxin-based models of Parkinson’s disease. Neuroscience. 2012;211:51–76. PMID: 21397033.
9. Jackson-Lewis V, Blesa J, Przedborski S. Animal models of Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S183–5. PMID: 22166432.
10. Duty S, Jenner P. Animal models of Parkinson’s disease: a source of novel treatments. Br J Pharmacol. 2011;164(4):1357–91. PMID: 21457235.
11. Przedborski S. Pathogenesis of Parkinson’s disease. Eur J Neurosci. 2007;26(6):1501–14. PMID: 17880310.
12. Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson’s disease. Handb Exp Pharmacol. 2011;201:61–84. PMID: 21253404.
13. Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson’s disease. Neuroscientist. 2002;8(3):192–7. PMID: 12088155.
14. Cannon JR, Greenamyre JT. Neurotoxic pesticides and Parkinson’s disease. Neurobiol Dis. 2010;37(1):198–206. PMID: 19857568.
15. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson’s disease risk. Environ Health Perspect. 2011;119(6):866–72. PMID: 21269927.
16. Richardson JR, Quan Y, Sherer TB, Greenamyre JT. Paraquat neurotoxicity. J Neurochem. 2005;93(3):717–25. PMID: 15836627.
17. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson’s disease. Exp Neurol. 2002;177(2):518–29. PMID: 12429250.
18. Glinka Y, Gassen M, Youdim MBH. Mechanism of 6-OHDA neurotoxicity. J Neural Transm. 1996;103(7):917–24. PMID: 8895151.
19. Thirugnanam T, Santhakumar K. Chemically induced models of Parkinson’s disease. Comp Biochem Physiol C Toxicol Pharmacol. 2022; 258:109386. PMID: 34673252.
20. Schapira AHV. Mitochondrial dysfunction in Parkinson’s disease. Lancet Neurol. 2008;7(1):97–109. PMID: 18093511.
21. Xu CL, Qu R, Zhang J, Li LF, Ma SP. Neuroprotective effects of madecassoside in early stage of Parkinson’s disease induced by MPTP in rats. Fitoterapia. 2013 Oct 1;90:112-8.
22. Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice. Neuroscience. 2014 Sep 26;277:747-54.
23. Dilip Kumar Pal, Determination of Brain Biogenic Amines in Cynodon Dactylon Pers. and Cyperus Rotundus L. Treated Mice, International Journal Of Pharmacy And Pharmaceutical Sciences, 2009, 1(1):190-197.
24. Raju TR, Kutty BM, Sathyaprabha TN, Shankarnarayana Rao BS. Brain and behavior. National Institute of Mental Health and neurosciences, Bangalore. 2004. Pp. 134-138.
25. EllmanG.L, Fiches F.T. Quantitative determination of peptides by sulfhydryl groups. BiochemBiophys. 1959; 82: 70-72.
26. King J. The phosphohydrolases-acid and alkaline phosphatases, PracticalClinical Enzymology, 1st ed. London; 1965: 191-208.